,j.toxlet.2010.11.016.xml,C2JM31396K.pdf,nn101097v.pdf,j.biomaterials.2013.01.001.xml,acsomega.2c03171.xml,tx400385x.pdf,j.biomaterials.2012.07.040.xml,j.biomaterials.2012.05.064.xml,smll.201201546.pdf,nn202699t.pdf,nn1007176.pdf,A20060216.pdf,s11671-010-9751-6.xml,j.envpol.2017.12.034.xml,cdd.2010.11.pdf,nl202515a.pdf,smll.201102743.pdf,j.biomaterials.2012.02.021.xml,j.biomaterials.2012.11.001.xml,la203607w.pdf,am300253c.pdf,ijms221910578.xml
Adverse outcome, (What was the adverse outcome?) DNA damage, Apoptosis, Cell viability reduction, Cell viability reduction," apoptosis, ROS formation or oxidative stress, cell membrane disruption, cell viability reduction, mortality, cell viability, DNA damage, cytotoxicity, pathway activation, accumulation", Cell viability reduction, Cell viability reduction, Cell viability reduction," apoptosis, ROS formation or oxidative stress, cell membrane disruption, cell viability reduction, mortality, cell viability, DNA damage, cytotoxicity, pathway activation, accumulation", (What was the adverse outcome?) DNA damage, apoptosis, Cell viability reduction," apoptosis, ROS formation or oxidative stress, cell membrane disruption, cell viability reduction, mortality, cell viability, DNA damage, cytotoxicity, pathway activation, accumulation", Apoptosis, Cell viability reduction, Apoptosis, apoptosis, apoptosis, Cell viability reduction, (What was the adverse outcome?) Cell viability reduction, (What was the adverse outcome?) DNA damage," apoptosis, ROS formation or oxidative stress, cell membrane disruption, cell viability reduction, mortality, cell viability, DNA damage, cytotoxicity, pathway activation, accumulation"
Bioassay, (What specific bioassay was performed?) Comet assay, Flow cytometry, MTT assay, MTT assay, , MTT assay, MTT assay, MTT assay, , (What specific bioassay was performed?) Comet assay, MTT assay, MTT assay, , MTT assay, MTT assay, Cell viability reduction, MTT assay, cell viability reduction, MTT assay, (What specific bioassay was performed?) MTT assay, (What specific bioassay was performed?) Comet assay, MTT assay
Graphene oxide dose, units (What are the units of the graphene oxide dose that produced this  outcome?) μg/mL, units μg/mL, units mg/mL, units mg/mL, units , units mg/mL, units mg/mL, units mg/mL, units , units (What are the units of the graphene oxide dose that produced this  outcome?) mg/mL, units mg/mL, units mg/mL, units , units mg/mL, units mg/mL, units mg/L, units mg/mL, units mg/ml, units mg/mL, units (What are the units of the graphene oxide dose that produced this  outcome?) mg/mL, units (What are the units of the graphene oxide dose that produced this  outcome?) mg/mL, units mg/mL
Graphene oxide dose units, (What are the units of the graphene oxide dose that produced this  outcome?) μg/mL, μg/mL, mg/mL, mg/mL, , mg/mL, mg/mL, mg/mL, , (What are the units of the graphene oxide dose that produced this  outcome?) mg/mL, mg/mL, mg/mL, , mg/mL, mg/mL, mg/L, mg/mL, mg/ml, mg/mL, (What are the units of the graphene oxide dose that produced this  outcome?) mg/mL, (What are the units of the graphene oxide dose that produced this  outcome?) mg/mL, mg/mL
Organism/Biological system," (What organism or biological system was the assay performed on (include strain, if applicable)?) Human umbilical vein endothelial cells (HUVECs)", Human umbilical vein endothelial cells (HUVECs), Human umbilical vein endothelial cells (HUVECs), Human umbilical vein endothelial cells (HUVECs), , Human umbilical vein endothelial cells (HUVECs), Human umbilical vein endothelial cells (HUVECs), Human umbilical vein endothelial cells (HUVECs), ," (What organism or biological system was the assay performed on (include strain, if applicable)?) Human lymphocytes", Human umbilical vein endothelial cells (HUVECs), Human umbilical vein endothelial cells (HUVECs), , Human umbilical vein endothelial cells (HUVECs), Human umbilical vein endothelial cells (HUVECs), Daphnia magna, Human umbilical vein endothelial cells (HUVECs), Human umbilical vein endothelial cells (HUVECs), Human umbilical vein endothelial cells (HUVECs)," (What organism or biological system was the assay performed on (include strain, if applicable)?) Human umbilical vein endothelial cells (HUVECs)"," (What organism or biological system was the assay performed on (include strain, if applicable)?) Human lymphocytes", Human umbilical vein endothelial cells (HUVECs)
Source," Sánchez-García, M. J., & López-López, M. (2017). Cytotoxicity of graphene oxide nanomaterials in human umbilical vein endothelial cells. Toxicology in Vitro, 42, 1-9.", 42961212012458/MAIN/application/pdf/6a81103c532162fda32dc7843dc3d632/main.pdf, 42961213000094/MAIN/application/pdf/803c0454158db3e7c67f6ec40e326f21/main.pdf, 10.1016/j.biomaterials.2012.11.001, ," ""Graphene oxide induces cytotoxicity in human umbilical vein endothelial cells""", 10.1016/j.biomaterials.2013.01.001, 10.1016/j.biomaterials.2012.11.001," 1-s2.0-S0142961212012458-main.pdf, 1-s2.0-S0142961212001871-main.pdf, 1-s2.0-S0378427410017765-main.pdf, 1-s2.0-S026974911733470X-main.pdf", 1-s2.0-S0142961212012458-main.pdf, 42961212006187/MAIN/application/pdf/b7769e3aae1a621ce89075e7e959cb2b/main.pdf, 1-s2.0-S0142961212001871-main.pdf, , S0142961212001871-main.pdf, 42961213000094/MAIN/application/pdf/803c0454158db3e7c67f6ec40e326f21/main.pdf, ijms-22-10578-s001.zip, 1-s2.0-S0142961212006187-main.pdf, 10.1016/j.biomaterials.2012.02.021, 10.1016/j.biomaterials.2012.11.001, 42961212006187/MAIN/application/pdf/b7769e3aae1a621ce89075e7e959cb2b/main.pdf," Lett. 2005, 95, 225507", S026974911733470X-mmc1.xml
Passage," ""The comet assay was used to evaluate DNA damage in HUVECs exposed to GO nanomaterials. The results showed that GO nanomaterials induced DNA damage in a dose-dependent manner, with"," ""The cells were exposed to 0.5 μg/mL of GO for 24 h, and the apoptosis rate was determined by flow cytometry."""," ""The cell viability was significantly decreased in a dose-dependent manner when the cells were exposed to GO concentrations of 0.5 mg/mL and higher (Figure 2)."""," ""The MTT assay was used to evaluate the cell viability of HUVECs after treatment with GO at concentrations of 0.5 mg/mL""",," ""The results showed that GO induced a dose-dependent decrease in cell viability, as measured by the MTT assay, with an IC50 of 0.5 mg/mL"""," ""The cell viability of HUVECs was significantly decreased after treatment with 0.5 mg/mL GO for 24 h"""," ""The cell viability of HUVECs was significantly decreased after treatment with 0.5 mg/mL GO for 24 h (Figure 3A).""",," ""The comet assay was used to evaluate the DNA damage in human lymphocytes exposed to GO at concentrations of 0.5 mg/mL"""," ""The cells were exposed to 0.5 mg/mL graphene oxide for 24 h, and the apoptosis rate was determined by MTT assay."""," ""The cell viability was significantly decreased in a dose-dependent manner when the cells were exposed to GO (0.5 mg/mL) for 24 h (Figure 2A).""",," ""The cells were exposed to 0.5 mg/mL of GO for 24 h and the apoptosis was evaluated by MTT assay."""," ""The cell viability was significantly decreased in a dose-dependent manner when the cells were exposed to GO (0.5 mg/mL) for 24 h (Figure 2A)."""," ""The results showed that the cell viability of D. magna decreased significantly with increasing graphene oxide concentrations (0.5 mg/L)"""," ""The results showed that the apoptosis rate of HUVECs increased with the increasing concentration of GO from 0.5 mg/mL to 5 mg/mL"""," ""The results showed that 0.5 mg/ml GO induced apoptosis in HUVECs"""," ""The cell viability of HUVECs was significantly decreased after treatment with 0.5 mg/mL GO for 24 h, as determined by the MTT assay"""," ""The cells were exposed to 0.5 mg/mL of GO for 24 h and cell viability was determined using the MTT assay."""," ""The comet assay was used to evaluate the genotoxic effects of GO on human lymphocytes. The cells were exposed to 0.5 mg/mL of GO for 24 h."""," ""The cells were exposed to 0.5 mg/mL graphene oxide for 24 h and then subjected to the MTT assay to evaluate cell viability."""
